+ Site Statistics
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Host responses and persistence of vector genome following intrabronchial administration of an E1(-)E3(-) adenovirus gene transfer vector to normal individuals

Host responses and persistence of vector genome following intrabronchial administration of an E1(-)E3(-) adenovirus gene transfer vector to normal individuals

Molecular Therapy 3(2): 206-215

Adenovirus (Ad)-mediated gene transfer to the respiratory epithelium of experimental animals and to nasal and airway epithelium of individuals with cystic fibrosis is followed by transient gene expression. Extensive studies in experimental animals are consistent with the concept that local cellular host anti-vector immune responses account for this short-term expression, and systemic and local [lung epithelial lining fluid (ELF)] anti-Ad neutralizing antibodies are generated following Ad vector administration to the respiratory epithelial surface. To determine if this paradigm holds in normal humans, a first-generation Ad vector (Ad(GV)CD.10, an E1(-)E3(-) Ad serotype 5-based vector coding for the Escherichia coli cytosine deaminase gene) was sprayed locally in escalating doses (8 x 10(8)-8 x 10(10) particle units (pu), n = 2/group) into the lung airway epithelium of six normal individuals. Serum, ELF, and endobronchial biopsies were obtained at baseline and at various time points following vector administration. In contrast to the observations in experimental animals in which lung administration of first-generation Ad vectors is followed by strong systemic and local host response, bronchial spray administration of the Ad vector to normal humans showed: (1) minimal inflammation in bronchial biopsies, bronchial brushing, and bronchoalveolar lavage fluid; (2) no blood lymphocyte proliferation in five of six individuals in response to in vitro stimulation with Ad antigens; and (3) no significant increase from baseline in blood or lung ELF anti-Ad neutralizing antibodies. Despite this minimal normal human anti-Ad host response, dose-dependent levels of vector DNA in the airway epithelium were transient. Vector DNA in the targeted airway epithelial cells peaked in a dose-dependent fashion at 0.007 to 1.1 copies/cell at day 7 and declined thereafter, reducing to <10% of peak levels by 2 weeks. These observations demonstrate both the strengths and the limits of using experimental animals to predict human responses to gene transfer vectors. While the transient nature of Ad vector persistence in the airway epithelium is predicted by most experimental animal studies, respiratory epithelial administration of first-generation Ad vectors at doses up to 10(10) pu to airway epithelium of healthy individuals elicits minimal to no detectable systemic and mucosal humoral and cellular immune responses, an observation diametrically opposed to the host responses measured in experimental animals. These findings suggest that, while adaptive anti-Ad immune responses likely play some role in the disappearance of the vector DNA following vector administration to the human lung, other mechanisms may also be involved in the response of humans to Ad gene transfer vectors.

(PDF emailed within 0-6 h: $19.90)

Accession: 046274919

Download citation: RISBibTeXText

PMID: 11237677

DOI: 10.1006/mthe.2000.0244

Related references

Cellular immune responses of healthy individuals to intradermal administration of an E1-E3- adenovirus gene transfer vector. Human Gene Therapy 10(17): 2823-2837, 1999

Modification of nasal epithelial potential differences of individuals with cystic fibrosis consequent to local administration of a normal CFTR cDNA adenovirus gene transfer vector. Human Gene Therapy 6(11): 1487-1496, 1995

"Sero-switch" adenovirus-mediated in vivo gene transfer: circumvention of anti-adenovirus humoral immune defenses against repeat adenovirus vector administration by changing the adenovirus serotype. Human Gene Therapy 7(1): 79-87, 1996

Adenovirus serotype 35 Genome sequence and gene transfer vector development. Cancer Gene Therapy 10(Supplement 1): S21, January, 2003

Feasibility of inner ear gene transfer after middle ear administration of an adenovirus vector. Laryngo- Rhino- Otologie 80(8): 431-435, 2001

Effective tumor targeted gene transfer using PEGylated adenovirus vector via systemic administration. Journal of Controlled Release 122(1): 102-110, 2007

Erythropoietin gene transfer and expression in adult normal mice: use of an adenovirus vector. Human Gene Therapy 5(8): 979-985, 1994

Integration into the host cell genome and sustained persistence in episomal forms of an AAV based vector containing the human multidrug resistance gene. British Journal of Haematology 93(SUPPL 2): 333, 1996

Adenovirus-mediated gene transfer for cystic fibrosis: quantitative evaluation of repeated in vivo vector administration to the lung. Gene Therapy 1(3): 192-200, 1994

Transfer of beta-amyloid precursor protein gene using adenovirus vector causes mitochondrial abnormalities in cultured normal human muscle. Proceedings of the National Academy of Sciences of the United States of America 93(3): 1314-1319, 1996

Modulation of gene expression after replication-deficient, recombinant adenovirus-mediated gene transfer by the product of a second adenovirus vector. Gene Therapy 2(2): 124-131, 1995

Angiogenesis gene therapy: Phase I assessment of direct intramyocardial administration of an adenovirus vector expressing VEGF121 cDNA to individuals with clinically significant severe coronary artery disease. Circulation 100(5): 468-474, Aug 3, 1999

Very large capacity adenovirus vector-mediated gene transfer to skeletal muscles produces higher early transduction level when compared to gene delivery by first generation adenovirus. Neurology 52(6 SUPPL 2): A326, April 12, 1999